A guide to getting digital records right—every day

Data integrity is the backbone of compliant manufacturing. The FDA expects drug manufacturers to generate reliable, accurate records across the entire data lifecycle, and it has formalized those expectations in guidance and regulation. This article explains how ALCOA principles fit into the FDA’s view of data integrity, how those principles relate to 21 CFR Part 11, and what practical steps you can take to make the right way the easy way for your team.

Why data integrity matters (and what FDA expects)

The FDA’s 2018 guidance clarifies that data used to demonstrate cGMP compliance must be complete, consistent, and accurate—from creation through archival—and that firms should apply risk-based controls to prevent and detect issues. In practice, that means your QC program should make it straightforward to capture, protect, review, and retrieve the records that underpin product quality decisions.

Where 21 CFR Part 11 fits

21 CFR Part 11 sets the criteria under which the FDA considers electronic records and electronic signatures to be trustworthy, reliable and generally equivalent to paper records and handwritten signatures. It applies to records created, modified, maintained, archived, retrieved or transmitted under FDA recordkeeping requirements. The FDA first issued the final rule in March 1997 and later published “Scope and Application” (2003), signaling a risk-based, enforcement-discretion approach while it reexamined certain provisions.

ALCOA—FDA’s shorthand for data that can be trusted

In its 2018 Data Integrity Q&A guidance, the FDA defines data integrity and explicitly anchors it to ALCOA—records that are Attributable, Legible, Contemporaneously recorded, Original (or a true copy) and Accurate. The FDA uses ALCOA to frame what “good looks like” for cGMP data and ties each attribute to specific parts of the regulations for finished pharmaceuticals and positron emission tomography (PET) drugs.

ALCOA in one line: Every cGMP datum should clearly show who did what, when, with what equipment or materials, and it should be readable, original (or a verified true copy), and correct.

Turning ALCOA into everyday controls

Below are pragmatic controls that align with 21 CFR Part 11 and ALCOA. You can use them to reduce manual touchpoints, create defensible records and simplify audits

• Enforce unique user IDs; avoid shared logins. The FDA warns that shared accounts undermine attribution and are frequently cited.
• Configure role-based access and document who can do what, where and when.

• Store records in durable, readable formats and preserve the metadata needed to reconstruct activities (e.g., user, instrument ID, date/time).
• Contemporaneous
• Capture data at the time of performance with secure, timestamped audit trails; synchronize system clocks according to site policy.

• Retain original electronic records (not just printouts) from standalone instruments when those records are the cGMP records of interest; validated true copies are acceptable when originals can’t be retained.

• Validate computerized systems for their intended use; control calculations, versioning and configurations; review audit trails with the record.
• Regulatory observations often trace back to a few recurring gaps: disabled audit trails, shared accounts, backdating, unreported failures, “testing into compliance,” and weak investigation practices. To avoid these common pitfalls, it’s important to establish technical controls to prevent these behaviors and train reviewers from spotting them.

Starting (or accelerating) your digital transition

A practical roadmap:

1. Lead with risk assessment. Identify critical records and where attribution, legibility, timing, originality and accuracy can fail; implement proportionate controls.

2. Define what constitutes the original record in each workflow and how true copies are created, verified, and retained.

3. Choose systems that make compliance easy. Favor solutions with role-based access, audit trails, automatic time stamps, metadata capture and validated exports. FDA’s 2003 Part 11 guidance endorses risk-based validation and fit-for-purpose controls.

4. Document, then demonstrate. Ensure procedures specify who reviews what, when and how (including audit trail review), and regularly show it in practice.

Frequently asked questions

Can I “buy” Part 11 compliance?

No. Vendors can enable compliance with features like audit trails, and access controls and secure storage, but your procedures, training and usage determine compliance. The FDA stresses management’s role in building a culture that prevents data integrity problems and corrects them when they occur.

Do I need to keep original electronic files if I print the results?

Yes, if the original electronic record is the cGMP record of interest, retain it with metadata; don’t rely on paper printouts alone. Validated true copies are acceptable where appropriate.

How often should we review audit trails?

The FDA expects routine, meaningful audit trail review—by qualified personnel and at appropriate intervals tied to the record’s use (e.g., at the time of result review or batch release).

A quick ALCOA/Part 11 review checklist

Use this as a non-exhaustive starting point for gap-spotting:

• Users have unique credentials; shared accounts are prohibited.
• Systems timestamp actions and maintain secure audit trails; reviewers actually review them.
• Original electronic records (and true copies) are retained with metadata for the full retention period.
• Procedures define when a record is original, how copies are verified and how backups are protected.
• Computerized workflows are validated according to risk; changes are controlled and documented.

Bottom line

Think of ALCOA as a design target for every cGMP record. Pair those attributes with 21 CFR Part 11 technical and procedural controls, and you’ll make it easier for your team to produce records that stand up to scrutiny—day in, day out.

Ready to keep learning about ALCOA and 21 CFR Part 11 compliance? Watch the webinar: